Literature DB >> 15555833

Healthcare-associated pneumonia in adults: management principles to improve outcomes.

Donald E Craven1, Richard Palladino, Daniel P McQuillen.   

Abstract

Guidelines for Management of HAP were developed jointly by the ATS and IDSA in 2004. These guidelines were designed to improve patient outcomes and to decrease the emergence of MDR pathogens (see Fig. 1).Principles include early initiation of appropriate and adequate antibiotic therapy after cultures of blood and sputum are obtained. Quantitative distal airway sampling by bronchoscopy provides greater diagnostic specificity for VAP: in one randomized study, improved outcomes were noted, compared with clinical diagnosis with qualitative endotracheal aspirates. Higher doses of initial, empiric antibiotics also are recommended. Assessment of the patient's clinical response to empiric antibiotics should be correlated with microbiologic results to streamline, de-escalate, or stop unnecessary anti-biotic treatment. Duration of therapy for uncomplicated HAP should be limited to 7 days followed by close monitoring for relapse after cessation of antibiotics. The authors suggest that prevention strategies target modifiable short- and long-term risk factors. They also advocate the use of a multidisciplinary team that is dedicated to the treatment and prevention of HCAP and the basic principle of the modern Hippocratic Oath: "I will prevent disease whenever I can, for prevention is preferable to cure."

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15555833     DOI: 10.1016/j.idc.2004.08.001

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  8 in total

1.  CURB-65 pneumonia severity assessment adapted for electronic decision support.

Authors:  Barbara E Jones; Jason Jones; Thomas Bewick; Wei Shen Lim; Dominik Aronsky; Samuel M Brown; Wim G Boersma; Menno M van der Eerden; Nathan C Dean
Journal:  Chest       Date:  2010-12-16       Impact factor: 9.410

Review 2.  Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit.

Authors:  S V Yakovlev; L S Stratchounski; G L Woods; B Adeyi; K A McCarroll; J A Ginanni; I R Friedland; C A Wood; M J DiNubile
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-10       Impact factor: 3.267

4.  Intermediate risk of multidrug-resistant organisms in patients who admitted intensive care unit with healthcare-associated pneumonia.

Authors:  Hongyeul Lee; Ji Young Park; Taehoon Lee; Yeon Joo Lee; Hyo-Jeong Lim; Jong Sun Park; Ho Il Yoon; Jae-Ho Lee; Choon-Taek Lee; Young-Jae Cho
Journal:  Korean J Intern Med       Date:  2016-03-11       Impact factor: 2.884

5.  Invention and Pilot Study of the Efficacy and Safety of the SUPRAtube Device in Continuous Supraglottic Aspiration for Intubated and Mechanically Ventilated Patients.

Authors:  Alba Ramírez-Sarmiento; Orlando Aya; Diana Cáceres-Rivera; Carlos F Reyes; Angela Espitia; Camilo Pizarro; Joaquim Gea; Victor R Castillo; Mauricio Orozco-Levi
Journal:  Med Devices (Auckl)       Date:  2021-10-05

6.  The value of a risk model for early-onset candidemia.

Authors:  Christian Sandrock; Javeed Siddiqui
Journal:  Crit Care       Date:  2009-11-16       Impact factor: 9.097

7.  Update on the appropriate use of linezolid in clinical practice.

Authors:  Roberto Manfredi
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

8.  Assessment of thoracic ultrasound in complementary diagnosis and in follow up of community-acquired pneumonia (cap).

Authors:  Maria D'Amato; Gaetano Rea; Vincenzo Carnevale; Maria Arcangela Grimaldi; Anna Rita Saponara; Eric Rosenthal; Michele Maria Maggi; Lucia Dimitri; Marco Sperandeo
Journal:  BMC Med Imaging       Date:  2017-08-31       Impact factor: 1.930

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.